Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.
The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.
The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.
Publications found:
167
Sort by:
Hereceptin Biosimilar-Europe Market Status and Trend Report 2013-2023
US$ 3,480.00
... Hereceptin Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges The report segments the Europe Hereceptin Biosimilar market as: Europe Hereceptin ...
December 2017
135 pages
Hereceptin Biosimilar-India Market Status and Trend Report 2013-2023
US$ 2,980.00
... Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges The report segments the India Hereceptin Biosimilar market as: India Hereceptin Biosimilar Market ...
December 2017
146 pages
Hereceptin Biosimilar-North America Market Status and Trend Report 2013-2023
US$ 3,480.00
... Hereceptin Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges The report segments the North America Hereceptin Biosimilar market as: North America ...
December 2017
154 pages
Hereceptin Biosimilar-South America Market Status and Trend Report 2013-2023
US$ 3,480.00
... Hereceptin Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges The report segments the South America Hereceptin Biosimilar market as: South America ...
December 2017
159 pages
Hereceptin Biosimilar-United States Market Status and Trend Report 2013-2023
US$ 3,480.00
... Hereceptin Biosimilar market Market status and development trend of Hereceptin Biosimilar by types and applications Cost and profit status of Hereceptin Biosimilar, and marketing status Market growth drivers and challenges The report segments the United States Hereceptin Biosimilar market as: United States ...
December 2017
133 pages
Bevacizumab Biosimilar-Asia Pacific Market Status and Trend Report 2013-2023
US$ 3,480.00
... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the Asia Pacific Bevacizumab Biosimilar market as: Asia Pacific ...
November 2017
147 pages
Bevacizumab Biosimilar-China Market Status and Trend Report 2013-2023
US$ 2,980.00
... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the China Bevacizumab Biosimilar market as: China Bevacizumab ...
November 2017
157 pages
Bevacizumab Biosimilar-Europe Market Status and Trend Report 2013-2023
US$ 3,480.00
... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the Europe Bevacizumab Biosimilar market as: Europe Bevacizumab ...
November 2017
133 pages
Bevacizumab Biosimilar-India Market Status and Trend Report 2013-2023
US$ 2,980.00
... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the India Bevacizumab Biosimilar market as: India Bevacizumab ...
November 2017
138 pages
Bevacizumab Biosimilar-North America Market Status and Trend Report 2013-2023
US$ 3,480.00
... Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the North America Bevacizumab Biosimilar market as: North America Bevacizumab Biosimilar ...
November 2017
135 pages
Bevacizumab Biosimilar-South America Market Status and Trend Report 2013-2023
US$ 3,480.00
... Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the South America Bevacizumab Biosimilar market as: South America Bevacizumab Biosimilar ...
November 2017
160 pages
Bevacizumab Biosimilar-United States Market Status and Trend Report 2013-2023
US$ 3,480.00
... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the United States Bevacizumab Biosimilar market as: United ...
November 2017
158 pages
Commercialisaton of Biosimilars: Multifunctional teamwork for success
US$ 2,245.00
... believe companies need to choose 'a road less travelled'? Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle reveals what ... to optimal strategy development and implementation for biosimilars Key insights As the biosimilar market matures, commercial strategies will evolve to ...
October 2017
Biosimilars Real World Evidence: Proving the point
US$ 2,245.00
... prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence. In Biosimilars Real World Evidence: Proving the point ...
June 2017
Biosimilars Market in India 2017
US$ 950.00
... Netscribes’ latest market research report titled Biosimilars Market in India 2017, describes the current and forecasted dynamics of the biosimilars market in India. The increasing ... has resulted in the growth of this industry in India. Biosimilars are typically marketed at prices that are 25% to 40% below the ...
April 2017
43 pages
Biosimilars in Emerging Markets
US$ 2,245.00
... emerging-market industry Pipeline of biosimilar monoclonal antibodies in emerging markets Pipeline of non-monoclonal antibody biosimilars in emerging markets In market access, biosimilar players face different challenges to originators Funding & pricing attributes of leading emerging markets ...
February 2017
Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022
US$ 2,600.00
The Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 is a professional and in-depth study on the current state of the Biosimilar Drug Market. The report analysis the global market of Biosimilar Drug by main manufactures and geographic regions. The report includes Biosimilar Drug definitions, classifications, applications and ...
February 2017
105 pages
2017 Top 5 Biologics and Biosimilars Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
US$ 4,960.00
... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in North America, Europe, Asia ... , revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico ... , this report focuses on sales, market share and growth rate of Biologics and Biosimilars in each application, can be divided into Tumor Diabetes ...
December 2016
126 pages
2017-2022 Global Top Countries Biologics and Biosimilars Market Report
US$ 4,960.00
... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in United States, Canada, ... by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top 5 players in these Countries, from 2012 to 2017 ( ...
December 2016
126 pages
Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)
US$ 800.00
... “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share ... current and future trends. Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling ...
October 2016
58 pages
Enbrel Biosimilars Clinical Trial & Opportunity Insight
US$ 1,500.00
... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...
October 2016
70 pages
Humira Biosimilars Clinical Trial Insight
US$ 1,500.00
... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...
October 2016
80 pages
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
US$ 1,500.00
... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...
October 2016
85 pages
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
US$ 1,000.00
... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...
October 2016
35 pages
Remicade (Infliximab) Biosimilar Clinical Trial Insight
US$ 1,200.00
... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...
October 2016
50 pages
Global Biosimilar Market Outlook 2022
US$ 1,500.00
... recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field. As per RNCOS report “Global Biosimilar Market Outlook 2022”, the global biosimilars market is anticipated to witness a high double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market ...
September 2016
135 pages
EPO Biosimilars - The Future of Erythropoietin Market
US$ 600.00
... . However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost. As per RNCOS report “EPO Biosimilars - The ... segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available ...
August 2016
45 pages
Analyzing the Global Biosimilars Industry 2016
US$ 1,100.00
... biosimilars is growing. Aruvian Research analyzes the global biosimilars industry in its research report Analyzing the Global Biosimilars Industry 2016. In this research report, we analyze what biosimilars ... -wise analysis of the biosimilar industry. Biosimilar markets are analyzed in Australia, BRIC nations ...
July 2016
285 pages
The Future of Biosimilars 2016
US$ 2,195.00
... Understand the Forces Shaping the Biosimilars Market Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers ... biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars? Getting crowded: How will the market handle multiple biosimilars ...
June 2016
Сompetitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update
US$ 1,450.00
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ...
May 2016
462 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
US$ 335.00
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...
May 2016
74 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
US$ 280.00
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...
May 2016
56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
US$ 335.00
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...
May 2016
84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
US$ 560.00
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...
May 2016
124 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update
US$ 1,393.00
... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...
May 2016
462 pages
US Biosimilars Market Opportunity & Clinical Pipeline Analysis
US$ 2,400.00
... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...
February 2016
330 pages